PPARalpha agonist modulates lipid and nitridergic metabolism in term placenta from control and diabetics rats.

MARTÍNEZ NORA; CAPOBIANCO EVANGELINA; FERNANDEZ DO PORTO DARIO; JAWERBAUM ALICIA; GONZÁLEZ ELIDA

Los Cocos - Córdoba

Simposio; III Latin American Symposium on Maternal Fetal Interaction and Placenta: Basic & Clinical Research (SLIMP); 2007

Diabetes alters placental lipid and nitric oxide (NO) metabolism. PPARalpha is a nuclear receptor involved in lipid homeostasis. We aimed to evaluate whether PPARalpha agonists regulate lipid levels, NO production and lipid peroxidation in the placenta from control (C) and diabetic (D) rats at term. Methods: Diabetes was induced by streptozotocin administration to rat neonates (90 mg/kg). Placental explants obtained at term were cultured for 3h either with or without the PPARalpha agonists clofibrate (20 mM) and LTB4 (0.1 mM) for further analysis of 1) Lipid levels by TLC and densitometry, 2) NO production by measurement of nitrates/nitrites and 3) Lipid peroxidation by determination of thiobarbituric acid reactive substances (TBARs). Results: Both LTB4 and clofibrate reduced placental concentrations of cholesterol (p